公开(公告)号：US11319286B2

公开(公告)日：2022-05-03

申请号：US16635408

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Tatsuhiko Fujimoto ,  Kentaro Rikimaru ,  Koichiro Fukuda ,  Hiromichi Sugimoto ,  Takahiro Matsumoto ,  Yuichi Kajita ,  Satoshi Mikami ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Masaki Daini ,  Masaki Ogino ,  Kohei Takeuchi ,  Tohru Miyazaki ,  Yoshiteru Ito ,  Norihito Tokunaga ,  Takahiro Sugimoto ,  Tsuneo Oda ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Keisuke Imamura

IPC: C07D207/14 ,  C07D401/14 ,  C07D403/06 ,  A61P25/28

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US11034700B2

公开(公告)日：2021-06-15

申请号：US16491794

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Masaki Daini ,  Yuhei Miyanohana ,  Hideo Suzuki ,  Kenichiro Shimokawa ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: A61K31/40 ,  C07D491/107 ,  C07D207/12 ,  C07D207/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D409/06 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220017530A1

公开(公告)日：2022-01-20

申请号：US17475733

申请日：2021-09-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61P1/10 ,  A61K31/4355

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US09605000B2

公开(公告)日：2017-03-28

申请号：US14775265

申请日：2014-03-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shizuo Kasai ,  Masaki Ogino ,  Ryo Mizojiri ,  Takeshi Yamasaki ,  Hideki Hirose ,  Nobuyuki Takakura ,  Tohru Yamashita ,  Sachie Morimoto ,  Takashi Nakahata ,  Asato Kina

IPC: C07D498/10 ,  A61P3/00 ,  A61K31/424

CPC classification number: C07D498/10

Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

公开(公告)号：US11713311B2

公开(公告)日：2023-08-01

申请号：US17550173

申请日：2021-12-14

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18

CPC classification number: C07D409/12 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2095 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  C07D231/56 ,  C07D235/06 ,  C07D249/18 ,  C07D401/12

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I):




wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US11059780B2

公开(公告)日：2021-07-13

申请号：US16491811

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Daini ,  Yuhei Miyanohana ,  Satoshi Mikami ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: C07D207/12 ,  C07D405/12 ,  C07D403/12 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D403/14 ,  C07D493/08 ,  C07D487/10 ,  C07D498/10 ,  C07D471/04 ,  C07D413/12 ,  C07D491/107 ,  C07D487/08

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10214508B2

公开(公告)日：2019-02-26

申请号：US15318552

申请日：2015-06-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Tomoko Ashizawa ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Ryosuke Arai

IPC: C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  C07D213/81 ,  C07D405/12

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

公开(公告)号：US10548877B2

公开(公告)日：2020-02-04

申请号：US16083295

申请日：2017-03-09

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masaki Ogino ,  Eiji Kimura ,  Shinkichi Suzuki ,  Kouji Fuji ,  Tomohiro Ohashi ,  Makoto Fushimi ,  Kei Masuda ,  Tatsuki Koike ,  Takeshi Wakabayashi ,  Jinichi Yonemori ,  Masami Yamada

IPC: A61K31/4192 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/4406 ,  A61K31/4439 ,  A61P25/20 ,  A61P25/28 ,  A61P25/18 ,  A61P25/16 ,  C07D213/56 ,  C07D231/12 ,  C07D249/06 ,  C07D401/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12

Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.

公开(公告)号：US11236099B2

公开(公告)日：2022-02-01

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki Takami ,  Masaki Seto ,  Shinobu Sasaki ,  Haruhi Ando ,  Masaki Ogino ,  Tomoko Ohashi ,  Toshihiro Imaeda ,  Ikuo Fujimori ,  Yasuhiro Tsukimi ,  Masami Yamada ,  Kenichiro Shimokawa ,  Takeshi Wakabayashi ,  Masataka Murakami ,  Makoto Fushimi ,  Tomohiro Okawa ,  Jinichi Yonemori ,  Tomohiro Ohashi ,  Hideo Suzuki ,  Hironobu Maezaki ,  Ayumu Sato ,  Yasutomi Asano ,  Steve Swann

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11230541B2

公开(公告)日：2022-01-25

申请号：US16634402

申请日：2018-07-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji Kimura ,  Masaki Ogino ,  Yasuhisa Kohara ,  Tomoko Ohashi ,  Tomohiro Kaku ,  Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito

IPC: C07D409/12 ,  C07D401/12 ,  C07D249/18 ,  A61P25/28 ,  A61P25/24 ,  A61P25/06 ,  A61K9/20 ,  A61K9/48 ,  C07D231/56 ,  C07D235/06

Abstract: Provided is a heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.